Lymphoma, large b-cell, diffuse Trials in Atlanta, United States
Conditions / Lymphoma, large b-cell, diffuse / Atlanta, United States
Lymphoma, large b-cell, diffuse has been the subject of sustained clinical investigation across multiple research sites.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | COMPLETED | PHASE1 |
| NCT03483103 | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | COMPLETED | PHASE2 |
| NCT02413489 | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma | TERMINATED | PHASE2 |
| NCT00849147 | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | COMPLETED | PHASE2 |
| NCT02208037 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | COMPLETED | PHASE2 |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | TERMINATED | PHASE1/PHASE2 |
| NCT02592876 | Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma | TERMINATED | PHASE2 |
| NCT01421667 | A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | COMPLETED | PHASE2 |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | COMPLETED | PHASE1 |
| NCT00529503 | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | TERMINATED | PHASE2 |